Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476571 | 0.82 | HTR6 (0.36) | HTR6RNASEH1CES1MAOALMNA | |
| SCHEMBL2566227 | 0.82 | CES1 (0.50) | RNASEH1CES1MAOAHPGDALDH1A1 | |
| SCHEMBL6525907 | 0.78 | HTR6 (0.33) | HTR6RNASEH1 | |
| SCHEMBL4436441 | 0.76 | CES1 (0.43) | CES1MAOAHPGDNPC1RAB9A | |
| SCHEMBL28352725 | 0.76 | HSD17B10 (0.50) | CES1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL1748980 | 0.75 | ALDH1A1 (0.41) | MAOAHPGDALDH1A1KDM4ENPC1 | |
| SCHEMBL24362428 | 0.73 | HPGD (0.46) | CES1MAOAHPGDMAPTRAB9A | |
| SCHEMBL3614858 | 0.73 | RNASEH1 (0.36) | HTR6RNASEH1CES1MAOAALDH1A1 | |
| SCHEMBL7960264 | 0.72 | HTR6 (0.41) | HTR6CES1MAOAALDH1A1MAOB | |
| SCHEMBL4448887 | 0.72 | HTR6 (0.41) | HTR6CES1MAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031539-A | Pine bark polyphenol extract and preparation method and application thereof | 北京农学院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4373826-A1 | SULFONIMIDAMDE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117677622-A | Sulfonyl imide amide compounds and uses thereof | 基因泰克公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023004257-A1 | SULFONIMIDAMDE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| WO-2021150574-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| CN-112105654-A | Curable resin mixture, curable resin composition, and cured product thereof | 日本化药株式会社 | 2020-12-18 | — | — | CN | disclosed |
| EP-3191471-B1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2020031935-A1 | CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | 日本化薬株式会社 | 2020-02-13 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005101838-A2 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1221454-B1 | Process for producing polycarbonate | BAYER MATERIALSCIENCE AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1221454-A1 | Process for producing polycarbonate | Bayer Aktiengesellschaft (DE) | 2002-07-10 | — | — | EP | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | HTR6 1310/4885RNASEH1 2444/4885CES1 3594/4885 |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | HTR6 924/4885RNASEH1 2892/4885CES1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.